Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Aug;56(8):478-486.
doi: 10.3928/23258160-20250304-01. Epub 2025 May 15.

Early Outcomes After Initiation of Faricimab in Patients With Diabetic Macular Edema

Durga S Borkar  1   2 , David C Tabano  3 , Ferhina S Ali  4 , Theodore Leng  5 , Vincent Garmo  3 , Ayesha Ahmed  3 , Rachel Myers  2 , Jacqueline K Shaia  6   7 , Giulio Barteselli  3 , Rishi P Singh  6   7   8
Affiliations
Free article
Multicenter Study

Early Outcomes After Initiation of Faricimab in Patients With Diabetic Macular Edema

Durga S Borkar et al. Ophthalmic Surg Lasers Imaging Retina. 2025 Aug.
Free article

Abstract

Background and objective: This study evaluated treatment patterns and outcomes among patients with diabetic macular edema (DME) treated with the bispecific antibody faricimab in routine clinical practice in the United States.

Patients and methods: FARETINA-DME was a retrospective study among patients with DME initiating faricimab from February 2022 to June 2023 identified from the United States IRIS® Registry.

Results: Four thousand five hundred fourteen (4,514) patients (6,204 eyes) previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy and 691 treatment-naïve patients (851 eyes) were included. In previously treated eyes, mean ± SD visual acuity was 64.0 ± 18.3 letters at index and 65.3 ± 19.0 at faricimab injection 4. In treatment-naïve eyes, visual acuity improved from 60.3 ± 19.8 to 63.9 ± 18.5 letters (P < 0.01). Mean ± SD central subfield thickness improved from 364.3 ± 132.2 to 330.1 ± 121.2 μm in previously treated eyes and 359.6 ± 115.0 to 307.4 ± 114.6 μm in treatment-naïve eyes (both P < 0.01).

Conclusions: In patients with DME receiving faricimab, visual acuity was maintained in previously treated and improved in treatment-naïve eyes. Both groups had anatomical improvement.

PubMed Disclaimer

Conflict of interest statement

Disclosure: DSB is a consultant for Alimera Sciences, 4DMT, AbbVie/Allergan, Boehringer Ingelheim, Apellis, Glaukos, Genentech, Iveric Bio, ONL Therapeutics, Regeneron, and Verana Health; is a speaker for Iveric Bio; and has received honoraria from Astellas and equipment or materials from Genentech. DCT is an employee of and holds stock options in Genentech. FSA is a consultant for Genentech, Iveric Bio, AbbVie/Allergan, OcuTera, Apellis, OptoMed, EyePoint, and Regeneron; is a speaker for Apellis and Iveric Bio; and has received equipment or materials from Genentech. TL has received grants from Astellas; is a consultant for Roche/Genentech, Iridex, Alcon, Protagonist Therapeutics, Aptitude Medical, Verana Health, Boehringer Ingelheim, Regeneron, Topcon, Apellis, and Virtual Field; is on an advisory board for Astellas and Nanoscope Therapeutics; and has received equipment or materials from Genentech. VG is an employee of and holds stock options in Genentech. AA is an employee of and holds stock options in Genentech. RM is a consultant for Genentech. JKS is a consultant for Genentech; and is a speaker for Impact Education for Regeneron. GB is an employee of and holds stock options in Genentech. RPS has received a research grant from Janssen; and is a consultant for Genentech, Bausch & Lomb, AbbVie, 4DMT, Alcon, Eyepoint, Apellis, Iveric Bio, Ocuphire, Ocular Therapeutics, RegenXBio, Zeiss, and Regeneron.

Publication types

MeSH terms

LinkOut - more resources